BIO-TECHNE Corp TECH
Biological Products, (No Diagnostic Substances) · Nasdaq
Revenue
$1.16B
+2.0% YoY
Net income
$285.26M
+4.9% YoY
Total assets
$2.56B
-5.4% YoY
EPS
1.05
-40.3% YoY
Advertisement
Income Statement
| Period | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|
| Revenues | $1.16B | $902.67M | $586.49M | $289.46M | $1.14B | $852.96M | $549.53M | $276.94M |
| Gross Profit | $769.73M | $591.46M | $376.90M | $183.02M | $769.82M | $566.38M | $361.78M | $185.19M |
| SG&A Expense | $466.38M | $391.88M | $240.61M | $119.16M | $378.38M | $332.84M | $221.00M | $105.33M |
| Operating Income (Loss) | $206.69M | $126.11M | $87.41M | $39.99M | $298.94M | $160.86M | $93.87M | $55.86M |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | — | $91.08M | $68.49M | $33.60M | $285.26M | $127.52M | $78.46M | $50.99M |
| EPS (Diluted) | 1.05 | 0.57 | 0.42 | 0.21 | 1.76 | 0.79 | 0.49 | 0.31 |
Balance Sheet
| Period | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.56B | $2.56B | $2.56B | $2.56B | $2.70B | $2.70B | $2.70B | $2.70B |
| Current Assets | $608.30M | $608.30M | $608.30M | $608.30M | $617.42M | $617.42M | $617.42M | $617.42M |
| Cash & Equivalents | $162.19M | $162.19M | $162.19M | $162.19M | $151.79M | $151.79M | $151.79M | $151.79M |
| Accounts Receivable | $206.88M | $206.88M | $206.88M | $206.88M | $241.39M | $241.39M | $241.39M | $241.39M |
| Inventory | $189.45M | $189.45M | $189.45M | $189.45M | $179.73M | $179.73M | $179.73M | $179.73M |
| PP&E (Net) | $245.72M | $245.72M | $245.72M | $245.72M | $251.15M | $251.15M | $251.15M | $251.15M |
| Goodwill | $972.66M | $980.93M | $980.93M | $980.93M | $872.74M | $972.66M | $972.66M | $972.66M |
| Current Liabilities | $175.85M | $175.85M | $175.85M | $175.85M | $159.38M | $159.38M | $159.38M | $159.38M |
| Accounts Payable | $25.31M | $25.31M | $25.31M | $25.31M | $37.97M | $37.97M | $37.97M | $37.97M |
| Stockholders Equity | $1.97B | $1.92B | $1.92B | — | — | $1.97B | $1.97B | $2.07B |
Cash Flow Statement
| Period | 2026 FY | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $298.98M | $189.35M | $148.24M | $63.89M | $254.39M | $223.49M | $142.50M | $59.38M |
| Investing Cash Flow | $-203.03M | $-35.59M | $-26.72M | $-21.68M | $-265.65M | $-194.22M | $-177.78M | $-154.11M |
| Financing Cash Flow | $-122.40M | $-163.45M | $-95.41M | $-11.57M | $22.62M | $-62.30M | $-9.89M | $71.51M |
| Stock Repurchases | $80.04M | $175.67M | $75.63M | $24.00K | $19.56M | $80.04M | $80.04M | — |
Similar companies
Learn more
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Data is sourced from the U.S. SEC EDGAR public database. This site does not provide investment advice.